Skip to main content
. 2022 Jan 3;75:103801. doi: 10.1016/j.ebiom.2021.103801

Figure 2.

Figure. 2

Survival outcomes of HER2DX low- and high-risk groups in early-stage HER2-positive breast cancer. (a) DRFS in Short-HER dataset (n=434); (b) DFS in Short-HER dataset (n=434); (c) OS in Short-HER dataset (n=434); (d) DFS in an independent combined validation dataset (n=268).